Challenges in the development of companion diagnostics for neuropsychiatric disorders

Expert Review of Molecular Diagnostics

Volumn 11, Issue 8, 2011, Pages 829-837

  Nikolcheva, Tania ^a   Jäger, Stephan ^b   Bush, Theresa Ambrose ^c   Vargas, Gabriel ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c Roche Diagnostics Corporation   (United States)

Author keywords

ADNI; Alzheimer's disease; biomarkers; companion diagnostics; in vitro diagnostics; laboratory developed tests; NEWMEDS; public private partnerships

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; COLONY STIMULATING FACTOR 1; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 3; PRESENILIN; TAU PROTEIN;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID ANALYSIS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC TEST; ELECTROENCEPHALOGRAM; HUMAN; LABORATORY TEST; MENTAL DISEASE; MOLECULAR DIAGNOSIS; NEUROLOGIC DISEASE; REVIEW;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; HUMANS; MENTAL DISORDERS; MOLECULAR DIAGNOSTIC TECHNIQUES;

EID: 80054936178     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.11.67     Document Type: Review

References (73)

1. Cowan WM, Kandel ER. Prospects for neurology and psychiatry. JAMA 285(5), 594-600 (2001).
2. Fanous AH, Kendler KS. Genetic heterogeneity, modifier genes, and quantitative phenotypes in psychiatric illness: searching for a framework. Mol. Psychiatry 10(1), 6-13 (2005).
3. Avissar S, Schreiber G. Toward molecular diagnostics of mood disorders in psychiatry. Trends Mol. Med. 8(6), 294-300 (2002).
4. Rosenhan D. On being sane in insane places. Science 179(70), 250-258 (1973).
5. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 12(6), 594-603 (2011).
6. Study Group 1 of the Global Harmonization Task Force. Chapter 4: Definitions. In: Principles of In Vitro Diagnostic (IVD) Medical Device Classification(Final Document GHTF/SG1/N045:2008). Global Harmonization Task Force (2008).
7. Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat. Rev. Clin. Oncol. 8(7), 426-433 (2011).
8. Ernstoff MS. Been there, not done that - melanoma in the age of molecular therapy. N. Engl. J. Med. 364(26), 2547-2578 (2011).
9. Hong S, Han SB. Overcoming metastatic melanoma with BRAF inhibitors. Arch. Pharm. Res. 34(5), 699-701 (2011).
10. Westby M, Van Der Ryst E. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir. Chem. Chemother. 16(6), 339-354 (2005).
11. Nazari R, Joshi S. CCR5 as target for HIV-1 gene therapy. Curr. Gene Ther. 8(4), 264-272 (2008).
12. Fatkenheuer G, Pozniak AL, Johnson MA et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 11(11), 1170-1172 (2005). Describes the clinical data on a new approach to treat HIV through the use of entry inhibitors.
13. Hunt JS, Romanelli F. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1. Pharmacotherapy 29(3), 295-304 (2009).
14. Low AJ, Swenson LC, Harrigan PR. HIV coreceptor phenotyping in the clinical setting. AIDS Rev. 10(3), 143-151 (2008).
15. Paolinelli R, Corada M, Orsenigo F, Dejana E. The molecular basis of the blood brain barrier differentiation and maintenance. Is it still a mystery? Pharmacol. Res. 63(3), 165-171 (2011).
16. American Pyschiatric Association. Diagnostic and Statistical Manual of Mental Disorders. DSM-IV-TR Fourth Edition. American Pyschiatric Publishing, VA, USA (2000).
17. Puls I, Gallinat J. The concept of endophenotypes in psychiatric diseases meeting the expectations? Pharmacopsychiatry 41(Suppl. 1), S37-S43 (2008).
18. Braff DL, Light GA. The use of neurophysiological endophenotypes to understand the genetic basis of schizophrenia. Dialogues Clin. Neurosci. 7(2), 125-135 (2005).
19. Braddock L. The dexamethasone suppression test. Fact and artefact. Br. J. Psychiatry 148, 363-374 (1986).
20. Harmer CJ, O'Sullivan U, Favaron E et al. Effect of acute antidepressant administration on negative affective bias in depressed patients. Br. J. Psychiatry 166(10), 1178-1184 (2009).
21. Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Br. J. Psychiatry 161(7), 1256-1263 (2004).
22. Leuchter AF, Cook IA, Hunter AM, Korb AS. A new paradigm for the prediction of antidepressant treatment response. Dialogues Clin. Neurosci. 11(4), 435-446 (2009).
23. Ilani T, Ben-Shachar D, Strous RD et al. A peripheral marker for schizophrenia: increased levels of D3 dopamine receptor mRNA in blood lymphocytes. Proc. Natl Acad. Sci. USA 98(2), 625-628 (2001).
24. Brunoni AR, Lopes M, Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int. J. Neuropsychopharmacol. 11(8), 1169-1180 (2008).
25. Volpi S, Potkin SG, Malhotra AK, Licamele L, Lavedan C. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J. Clin. Psychiatry 70(6), 801-809 (2009).
26. Schwarz E, Guest PC, Rahmoune H et al. Identification of a biological signature for schizophrenia in serum. Mol. Psychiatry DOI: 10.1038/mp.2011.42 (2011) (Epub ahead of print). Details the molecular and bioinformatic analysis that enabled the identification of a serum protein-based diagnostic that separates schizophrenics from healthy individuals based on a blood test.
27. Schwarz E, Izmailov R, Spain M et al. Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark. Insights 5, 39-47 (2010).
28. Querfurth HW, Laferla FM. Alzheimer's disease. N. Engl. J. Med. 362(4), 329-344 (2010).
29. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580), 353-356 (2002).
30. Clark CM, Schneider JA, Bedell BJ et al. Use of florbetapir-PET for imaging b-amyloid pathology. JAMA 305(3), 275-283 (2011).
31. Klunk WE, Engler H, Nordberg A et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55(3), 306-319 (2004). Describes the first human study of a novel amyloid-imaging positron emission tomography ligand that binds to amyloid and led to further studies that showed that amyloid deposition started much earlier than previously thought.
32. Rowe CC, Ng S, Ackermann U et al. Imaging b-amyloid burden in aging and dementia. Neurology 68(20), 1718-1725 (2007).
33. Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat. Rev. 6(2), 67-77 (2010).
34. Mega MS, Chu T, Mazziotta JC et al. Mapping biochemistry to metabolism: FDG-PET and amyloid burden in Alzheimer's disease. Neuroreport 10(14), 2911-2917 (1999).
35. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. 6(3), 131-144 (2010).
36. Grimmer T, Riemenschneider M, Forstl H et al. b amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol. Psychiatry 65(11), 927-934 (2009).
37. Fagan AM, Mintun MA, Mach RH et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Ab42 in humans. Ann. Neurol. 59(3), 512-519 (2006). An important paper that shows that cerebrospinal fluid (CSF) biomarkers are correlated with the amyloid load as detected by positron emission tomography imaging using Pittsburgh Compound-B.
38. Forsberg A, Engler H, Almkvist O et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging 29(10), 1456-1465 (2008).
39. Strozyk D, Blennow K, White LR, Launer LJ. CSF Ab 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60(4), 652-656 (2003).
40. Tapiola T, Alafuzoff I, Herukka SK et al. Cerebrospinal fluid b-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch. Neurol. 66(3), 382-389 (2009).
41. Blom ES, Giedraitis V, Zetterberg H et al. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE e4/e4 genotype. Dement. Geriatr. Cogn. Disord. 27(5), 458-464 (2009).
42. Samgard K, Zetterberg H, Blennow K, Hansson O, Minthon L, Londos E. Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. Int. J. Geriatr. Psychiatry 25(4), 403-410 (2010).
43. Wallin AK, Hansson O, Blennow K, Londos E, Minthon L. Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease? Int. J. Geriatr. Psychiatry 24(6), 638-647 (2009).
44. Buerger K, Ewers M, Pirttila T et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129(Pt 11), 3035-3041 (2006).
45. Hampel H, Burger K, Pruessner JC et al. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch. Neurol. 62(5), 770-773 (2005).
46. Jack Jr CR, Knopman DS, Jagust WJ et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9(1), 119-128 (2010).
47. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5(3), 228-234 (2006). A very influential study that shows the ability of CSF biomarkers to predict the conversion from mild cognitive impairment to Alzheimer's disease.
48. Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O. Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. J. Alzheimers Dis. 21(4), 1119-1128 (2010).
49. Mattsson N, Zetterberg H, Hansson O et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302(4), 385-393 (2009).
50. Okonkwo OC, Mielke MM, Griffith HR et al. Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment. Arch. Neurol. 68(1), 113-119 (2011).
51. Shaw LM, Vanderstichele H, Knapik-Czajka M et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 65(4), 403-413 (2009).
52. Mattsson N, Zetterberg H, Blennow K. Lessons from multicenter studies on CSF biomarkers for Alzheimer's disease. Int. J. Alzheimer's Dis. 2010, pii: 610613 (2010).
53. Petersen RC, Trojanowski JQ. Use of Alzheimer disease biomarkers: potentially yes for clinical trials but not yet for clinical practice. JAMA 302(4), 436-437 (2009).
54. Mckhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34(7), 939-944 (1984).
55. Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6(8), 734-746 (2007). Influential paper describing the revised Alzheimer's disease criteria with the suggestion to include imaging and CSF biomarkers.
56. Albert MS, Dekosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association workgroup. Alzheimers Dement. 7(3), 270-279 (2011).
57. Isaac M, Vamvakas S, Abadie E, Jonsson B, Gispen C, Pani L. Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: cerebro-spinal fluid related biomarkers for drugs affecting amyloid burden. Eur. Neuropsychopharmacol. DOI: 10.1016/j.euroneuro.2011.08.003 (2011) (Epub ahead of print).
58. Craig-Schapiro R, Perrin RJ, Roe CM et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol. Psychiatry 68(10), 903-912 (2010).
59. Hye A, Lynham S, Thambisetty M et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129(Pt 11), 3042-3050 (2006).
60. Ray S, Britschgi M, Herbert C et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 13(11), 1359-1362 (2007).
61. Thambisetty M, Simmons A, Velayudhan L et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch. Gen. Psychiatry 67(7), 739-748 (2010).
62. Soares HD, Chen Y, Sabbagh M, Roher A, Schrijvers E, Breteler M. Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. Ann. NY Acad. Sci. 1180, 56-67 (2009).
63. Booij BB, Lindahl T, Wetterberg P et al. A gene expression pattern in blood for the early detection of Alzheimer's disease. J. Alzheimers Dis. 23(1), 109-119 (2011).
64. Aisen PS, Petersen RC, Donohue MC et al. Clinical core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement. 6(3), 239-246 (2010).
65. Trojanowski JQ, Vandeerstichele H, Korecka M et al. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement. 6(3), 230-238 (2010).
66. Lovestone S, Francis P, Kloszewska I et al. AddNeuroMed - the European collaboration for the discovery of novel biomarkers for Alzheimer's disease. Ann. NY Acad. Sci. 1180, 36-46 (2009).
67. Abbott A. Schizophrenia: the drug deadlock. Nature 468(7321), 158-159 (2010).
68. Hughes B. Novel consortium to address shortfall in innovative medicines for psychiatric disorders. Nat. Rev. Drug Discov. 8(7), 523-524 (2009).
69. Code of Federal Regulations Title 21www.accessdata.fda.gov/scripts/cdrh/ cfdocs/cfcfr/CFRSearch.cfm?FR=809.3
70. Directive 98/79 EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices http://eur-lex.europa.eu/ LexUriServ/LexUriServ.do?uri=CONSLEG:1998L0079:20031120:en:PDF
71. Draft Guidance for Industry and Food and Drug Administration Staff - In Vitro Companion Diagnostic Deviceswww.fda.gov/MedicalDevices/ DeviceRegulationandGuidance/GuidanceDocuments/ucm262292.htm
72. ClinicalTrials.gov: A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Diseasewww.clinicaltrials.gov/ct2/show/NCT00890890
73. NEWMEDS (Novel Methods leading to NeW MEdications in Depression and Schizophrenia) Presswww.newmeds-europe.com/en/9589.php